Advertisement

Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib

  • Tariq Al Shehri
  • Kimberly Gilmour
  • Florian Gothe
  • Sam Loughlin
  • Shahnaz Bibi
  • Andrew D. Rowan
  • Angela Grainger
  • Thivytra Mohanadas
  • Andrew J. Cant
  • Mary A. Slatter
  • Sophie Hambleton
  • Desa Lilic
  • Timothy R. LeahyEmail author
Original Article

Abstract

Mutations in the coiled-coil and DNA-binding domains of STAT1 lead to delayed STAT1 dephosphorylation and subsequently gain-of-function. The associated clinical phenotype is broad and can include chronic mucocutaneous candidiasis (CMC) and/or combined immunodeficiency (CID). We report a case of CMC/CID in a 10-year-old boy due to a novel mutation in the small ubiquitin molecule (SUMO) consensus site at the C-terminal region of STAT1 leading to gain-of-function by impaired sumoylation. Immunodysregulatory features of disease improved after Janus kinase inhibitor (jakinib) treatment. Functional testing after treatment confirmed reversal of the STAT1 hyper-phosphorylation and downstream transcriptional activity. IL-17 and IL-22 production was, however, not restored with jakinib therapy (ruxolitinib), and the patient remained susceptible to opportunistic infection. In conclusion, a mutation in the SUMO consensus site of STAT1 can lead to gain-of-function that is reversible with jakinib treatment. However, full immunocompetence was not restored, suggesting that this treatment strategy might serve well as a bridge to definitive therapy such as hematopoietic stem cell transplant rather than a long-term treatment option.

Keywords

STAT1 sumoylation combined immunodeficiency chronic mucocutaneous candidiasis 

Notes

Acknowledgments

The authors wish to acknowledge the good will of the patient and his parents for consenting to publication of this case report.

Author Contributions

TAS, ADR, DL: functional immunology laboratory experiments, manuscript preparation, and review.

SL, SB: NGS panel and Sanger sequencing of STAT1 gene, manuscript preparation, and review.

KG, AJC, MAS, TRL: manuscript preparation and review.

Funding Information

Authors DL and TAS were funded to undertake this research through a Medical Research Council Confidence in Concept Grant (Grant No. BH152850). Author TAS was funded by King Faisal Specialist Hospital & Research Centre grant, Saudi Arabia. Author FG was funded by Deutsche Forschungsgemeinschaft (GO2955/1-1 (F.G.)).

Compliance with Ethical Standards

Ethical approval was granted by the Great North Biobank (GNB), Reference No. 5458/10/H0906/22, and Newcastle Autoimmune Inflammatory Rheumatic Diseases (NAIRD) Research Biobank, Reference No. 10/H0106/30.

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

10875_2019_687_MOESM1_ESM.docx (421 kb)
ESM 1 (DOCX 420 kb)

References

  1. 1.
    Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635–48.CrossRefGoogle Scholar
  2. 2.
    van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LAB, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54–61.CrossRefGoogle Scholar
  3. 3.
    Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154–64.CrossRefGoogle Scholar
  4. 4.
    Smyth AE, Kaleviste E, Snow A, Kisand K, McMahon CJ, Cant AJ, et al. Aortic calcification in a patient with a gain-of-function STAT1 mutation. J Clin Immunol. 2018;38(4):468–70.CrossRefGoogle Scholar
  5. 5.
    Takezaki S, Yamada M, Kato M, Park MJ, Maruyama K, Yamazaki Y, et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol. 2012;189(3):1521–6.CrossRefGoogle Scholar
  6. 6.
    Depner M, Fuchs S, Raabe J, Frede N, Glocker C, Doffinger R, et al. The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in STAT1. J Clin Immunol. 2016;36:73–84.CrossRefGoogle Scholar
  7. 7.
    Meesilpavikkai K, Dik WA, Schrijver B, et al. A novel heterozygous mutation in the STAT1 SH2 domain causes chronic mucocutaneous candidiasis, atypically diverse infections, autoimmunity, and impaired cytokine regulation. Front Immunol. 2017;8:274.CrossRefGoogle Scholar
  8. 8.
    Al Dhanhani H, Al Shehri T, Lilic D, et al. Double trouble? CMC with a mutation in both AIRE and STAT1. J Clin Immunol. 2018;38(6):635–7.CrossRefGoogle Scholar
  9. 9.
    Sobh A, Chou J, Schneider L, Geha RS, Massaad MJ. Chronic mucocutaneous candidiasis associated with an SH2 domain gain-of-function mutation that enhances STAT1 phosphorylation. J Allergy Clin Immunol. 2016;138(1):297–9.CrossRefGoogle Scholar
  10. 10.
    Sampaio EP, Ding L, Rose SR, Cruz P, Hsu AP, Kashyap A, et al. Novel signal transducer and activator of transcription 1 mutation disrupts small ubiquitin-related modifier conjugation causing gain of function. J Allergy Clin Immunol. 2018;141(5):1844–1853 e1842.CrossRefGoogle Scholar
  11. 11.
    Weinacht KG, Charbonnier LM, Alroqi F, Plant A, Qiao Q, Wu H, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017;139(5):1629–1640 e1622.CrossRefGoogle Scholar
  12. 12.
    Zheng J, van de Veerdonk FL, Crossland KL, Smeekens SP, Chan CM, al Shehri T, et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur J Immunol. 2015;45(10):2834–46.CrossRefGoogle Scholar
  13. 13.
    Ungureanu D, Vanhatupa S, Kotaja N, et al. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood. 2003;102(9):3311–3.CrossRefGoogle Scholar
  14. 14.
    Ungureanu D, Vanhatupa S, Gronholm J, et al. SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood. 2005;106(1):224–6.CrossRefGoogle Scholar
  15. 15.
    Begitt A, Droescher M, Knobeloch KP, Vinkemeier U. SUMO conjugation of STAT1 protects cells from hyperresponsiveness to IFNgamma. Blood. 2011;118(4):1002–7.CrossRefGoogle Scholar
  16. 16.
    Higgins E, Al Shehri T, McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551–3.CrossRefGoogle Scholar
  17. 17.
    Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665–9.CrossRefGoogle Scholar
  18. 18.
    Gronholm J, Vanhatupa S, Ungureanu D, et al. Structure-function analysis indicates that sumoylation modulates DNA-binding activity of STAT1. BMC Biochem. 2012;13:20.CrossRefGoogle Scholar
  19. 19.
    Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131(6):1624–34.CrossRefGoogle Scholar
  20. 20.
    Uzel G, Sampaio EP, Lawrence MG, Hsu AP, Hackett M, Dorsey MJ, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol. 2013;131(6):1611–23.CrossRefGoogle Scholar
  21. 21.
    Mizoguchi Y, Tsumura M, Okada S, Hirata O, Minegishi S, Imai K, et al. Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis. J Leukoc Biol. 2014;95(4):667–76.CrossRefGoogle Scholar
  22. 22.
    Bernasconi AR, Yancoski J, Villa M, Oleastro MM, Galicchio M, Rossi JG. Increased STAT1 amounts correlate with the phospho-STAT1 level in STAT1 gain-of-function defects. J Clin Immunol. 2018;38(7):745–7.CrossRefGoogle Scholar
  23. 23.
    Zimmerman O, Olbrich P, Freeman AF, Rosen LB, Uzel G, Zerbe CS, et al. STAT1 gain-of-function mutations cause high total STAT1 levels with normal dephosphorylation. Front Immunol. 2019;10:1433.CrossRefGoogle Scholar
  24. 24.
    Zimmerman O, Rosler B, Zerbe CS, et al. Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease. Open Forum Infect Dis. 2017;4(4):ofx202.CrossRefGoogle Scholar
  25. 25.
    Bloomfield M, Kanderova V, Parackova Z, et al. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol. 2018;38:589–601.CrossRefGoogle Scholar
  26. 26.
    Mogensen TH. IRF and STAT transcription factors - from basic biology to roles in infection, protective immunity, and primary immunodeficiencies. Front Immunol. 2019;9:3047.CrossRefGoogle Scholar
  27. 27.
    Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity. 2011;35(5):806–18.CrossRefGoogle Scholar
  28. 28.
    Virtanen AT, Haikarainen T, Raivola J, et al. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15–32.CrossRefGoogle Scholar
  29. 29.
    Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2018:1–13.Google Scholar
  30. 30.
    Al Shehri T, Abinun M, Gennery AR, et al. Is gain-of-function STAT1 CMC an interferonopathy? Clin Exp Immunol. 2015;182(S1):15.Google Scholar
  31. 31.
    Kaleviste E, Saare M, Leahy TR, Bondet V, Duffy D, Mogensen TH, et al. Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined. Eur J Immunol. 2019;49(5):790–800.CrossRefGoogle Scholar
  32. 32.
    van de Veerdonk FL, Netea MG. Treatment options for chronic mucocutaneous candidiasis. J Inf Secur 2016:72 Suppl:S56–S60.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Tariq Al Shehri
    • 1
    • 2
  • Kimberly Gilmour
    • 3
  • Florian Gothe
    • 1
  • Sam Loughlin
    • 4
  • Shahnaz Bibi
    • 4
  • Andrew D. Rowan
    • 1
  • Angela Grainger
    • 1
  • Thivytra Mohanadas
    • 1
  • Andrew J. Cant
    • 1
    • 5
  • Mary A. Slatter
    • 1
    • 5
  • Sophie Hambleton
    • 1
    • 5
  • Desa Lilic
    • 1
  • Timothy R. Leahy
    • 6
    Email author
  1. 1.Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUK
  2. 2.Department of Pathology & Laboratory Medicine, Immunology LabKing Faisal Specialist Hospital & Research CentreRiyadhKingdom of Saudi Arabia
  3. 3.Department of Immunology, Camelia Botnar LaboratoriesGreat Ormond Street Hospital for ChildrenLondonUK
  4. 4.Regional Molecular Genetics LaboratoryGreat Ormond Street Hospital for ChildrenLondonUK
  5. 5.Department of Paediatric Immunology and BMTGreat North Children’s HospitalNewcastle upon TyneUK
  6. 6.Department of Paediatric Immunology and Infectious DiseasesChildren’s Health IrelandDublinIreland

Personalised recommendations